cold chain is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cold-chain practice relies on documented temperature ranges, calibrated monitoring, and minimized excursions. Shipments may use insulated boxes, phase-change materials, or dry ice, with data loggers to record conditions. Upon receipt, the recipient should verify the logger trace and place items into long-term storage promptly. Repeated warming and cooling during transfers can be more harmful than a single controlled excursion. For solutions, dividing material into single-use aliquots reduces the number of thawing and refreezing events and limits repeated opening of the same container.
Handling begins before a peptide arrives at the bench. Containers should be inspected for cracks, loose caps, or visible moisture, and labels should record identity, lot, and receipt date. Lyophilized material is often allowed to equilibrate to room temperature before opening to prevent condensation on the powder. Gloves and a clean workspace reduce contamination and static-related loss. Once opened, the vial may be purged with inert gas and resealed if the peptide is sensitive to oxygen or humidity. These steps are procedural safeguards rather than guarantees of stability.
Reconstitution introduces new risks because the peptide contacts solvent, air, and container surfaces. The chosen solvent should match the peptide's solubility profile, and buffer salts, pH, and ionic strength can affect dissolution and subsequent stability. Gentle mixing is preferred over vigorous vortexing, which can create interfaces and shear. If the solution is not clear, the cause may be incomplete dissolution, aggregation, or insoluble counter-ions rather than a simple concentration problem. Filtration is sometimes used, but filters can adsorb peptides and alter measured concentration.
After reconstitution, solutions are divided into single-use aliquots and stored at -80°C. Labels include peptide name, concentration, buffer composition, date, and lot number. Freeze-thaw cycles are minimized by thawing only the needed aliquot on ice or at room temperature. Some peptides benefit from the addition of a carrier protein, such as bovine serum albumin, or a cryoprotectant like glycerol to reduce adsorption to plastic. Glass vials with low-binding surfaces are preferred for dilute solutions. Shipping of frozen aliquots uses dry ice and insulated containers to maintain the cold chain.
Receiving a peptide shipment requires immediate inspection of the packaging and temperature indicators. Any deviation from the specified cold chain should be documented and investigated. Upon arrival, solid peptides are generally kept at -20°C, whereas liquid formulations are stored at -80°C. Vials should be kept upright and protected from light. Repeated warming and cooling of the entire container is avoided by preparing smaller working aliquots. A log of lot numbers, receipt dates, and storage locations supports traceability and quality control.
| Property | Value | Notes |
|---|---|---|
| Container material | Glass or polypropylene | Low-binding options reduce peptide adsorption |
| Typical shipping condition | Dry ice or gel packs | Choice depends on required temperature range |
| Light protection | Amber vial or foil wrap | Reduces photodegradation of sensitive residues |
| Reconstitution solvent | Water, buffer, or organic co-solvent | Depends on peptide solubility and assay requirements |
| Temperature monitoring | Data logger or indicator | Documents excursions during transport and storage |
Cold-chain shipping uses insulated containers, phase-change packs, and temperature indicators. Dry ice maintains -70 °C or lower but requires venting to avoid pressure buildup. Gel packs provide 2-8 °C for shorter transit. Upon arrival, recipients should record temperature indicators and transfer vials promptly to storage. Deviations from specified conditions should be documented and may require analytical re-check. The effect of a brief temperature excursion is peptide-specific and not always predictable from general rules.
Handling begins with receipt and inspection. Vials should be checked for damage, label integrity, and temperature history. Lyophilized peptides should be allowed to equilibrate to room temperature before opening to prevent condensation. Solutions should be prepared in a clean, calibrated environment using appropriate solvents. Personal protective equipment and containment reduce exposure and contamination. Documentation of lot number, date, and storage location supports traceability. The goal is to limit repeated temperature changes, moisture exposure, and microbial contamination.
Reconstitution solvent depends on peptide solubility and intended use; water, buffer, or small amounts of organic solvent may be needed. After dissolution, solutions are typically aliquoted into single-use portions to avoid repeated freeze-thaw cycles. Aliquots are stored at -20 °C or -80 °C, depending on stability. Labels include concentration, solvent, date, and operator. Sterile filtration may be used when microbial control is required, but filters can adsorb peptides. The optimal concentration and solvent are often determined empirically.
After reconstitution, solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. Aliquots should be labeled with peptide identity, concentration, solvent, and date, then stored at the temperature specified by the supplier or protocol. Many peptides tolerate -20 °C for short periods, while -80 °C is preferred for longer storage. Frost-free freezers are generally avoided because temperature fluctuations can stress samples. Aseptic technique and sterile filters reduce microbial contamination, though filtration can also remove aggregated material or bind some peptides.
Peptide handling begins with careful receipt and inventory. Containers should be inspected for damage, label information should match the certificate of analysis, and storage location should be recorded. Many lyophilized peptides are electrostatic and may cling to vial walls or weighing paper, which can complicate transfer. Allowing a cold vial to equilibrate to room temperature before opening reduces condensation on the contents. Clean tools, gloves, and a low-humidity workspace limit contamination and moisture exposure during manipulation.
Reconstitution is the process of dissolving a dried peptide in a suitable solvent. The choice of solvent depends on solubility, charge, and sequence; sterile water is common, while buffers or small amounts of organic solvent may be needed for hydrophobic peptides. Adding solvent gently down the vial wall and mixing by inversion or gentle swirling reduces foaming and shear. Vortexing or vigorous pipetting can denature some peptides or promote aggregation. The resulting solution should be visually inspected for particles, turbidity, and complete dissolution before use.
Invented by Adrien Philippe in 1842 and commercialized by Patek Philippe & Co. in the 1850s, the stem-wind, stem-set movement did away with the watch key which was a necessity for the operation of any pocket watch up to that point. The first stem-wind and stem-set pocket watches were sold during the Great Exhibition in London in 1851 and the first owners of these new kinds of watches were Queen Victoria and Prince Albert. Stem-wind, stem-set movements are the most common type of watch-movement found in both vintage and modern pocket watches. The mainstream transition to the use of stem-wind, stem-set watches occurred at around the same time as the end of the manufacture and use of the fusee watch. Fusee chain-driven timing was replaced with a mainspring of better quality spring steel (commonly known as the "going barrel") allowing for a more even release of power to the escape mechanism. The balance wheel and balance spring provide a separate function: to regulate the timing (or escape) of the movement.
== Lobbying == The company engages in lobbying in the United States. It also lobbies the Government of Ontario and House of Commons of Canada through Rubicon Strategy, a firm owned by Progressive Conservative Party of Ontario campaign manager Kory Teneycke. Pfizer lobbied various officials in the Government of British Columbia between April and November 2012, including then-premier Christy Clark, future premier John Horgan, future health minister Adrian Dix, and future deputy premier, minister of public safety and solicitor general Mike Farnworth. Notable lobbying organizations or think tanks to which the company has contributed include BIOTECanada, Bipartisan Policy Center, The Business Council, Business Council for the United Nations, Center on Budget and Policy Priorities, European Federation of Pharmaceutical Industries and Associations, Foundation for the National Institutes of Health, Global Health Council, Innovative Medicines Canada, International Federation of Pharmaceutical Manufacturers & Associations, National Health Council, Pharmaceutical Advertising Advisory Board, Pharmaceutical Research and Manufacturers of America, Reagan-Udall Foundation, U.S. Global Leadership Coalition, and World Economic Forum.
=== Persons with disabilities === During 2025, the Karnataka Labour Department worked on a proposed legislative framework for reservations for persons with disabilities in education and private-sector employment. The draft framework proposed up to 10 percent reservation in educational institutions and 5 percent in private-sector employment, subject to legislative and policy processes.
President Donald Trump has stated the goals of the war were to destroy Iran's ballistic missiles, eliminate their navy, prevent them from acquiring nuclear weapons, and to stop Iranian proxies from holding power. Trump asserted that Iran's ballistic missile program could endanger US allies "throughout the world", including Europe and American mainland. Pete Hegseth said that Iran would be capable of nuclear blackmail with their ballistic missiles if the US did not attack it. However, a Defense Intelligence Agency assessment determined that Iran would not be capable of building intercontinental ballistic missiles until 2035. Secretary of State Marco Rubio warned that Iran posed an "imminent threat" to US bases in the event of Israeli strikes on Iran, thereby portraying the war as a preemptive one. Mike Johnson, the Speaker of the United States House of Representatives and Rubio said that Israel was going to attack Iran, after which Iran's retaliations against US bases would have brought them into war anyway. Senator Mark Warner of the Senate Intelligence Committee who was briefed by Rubio before the war began said that there was no evidence that Iran was going to launch a pre-emptive strike against the US, and that the war was ultimately decided upon by Israel. Trump rejected these claims, stating that "I might have forced their hands.
==== Geneva Consensus Declaration ==== On 17 January, Lula withdrew Brazil from the Geneva Consensus Declaration on Promoting Women's Health and Strengthening the Family. Signed by Bolsonaro in 2020, the document stated that "there is no international right to abortion nor any international obligation on the part of States to finance or facilitate abortion". The document, which also limits families to only those formed by heterosexual couples, was signed by countries such as Saudi Arabia, Uganda, Egypt, Indonesia, Hungary, the United Arab Emirates, Sudan and Belarus, as well as the United States (which left the declaration in 2021), totaling 31 countries.
Sources: en.wikipedia.org
=== Phase 2/3 === Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor and cortisol synthesis inhibitor) and oxazepam (benzodiazepine/GABAA receptor positive allosteric modulator) – smoking withdrawal NFL-101 (tobacco leaf extract) – immunomodulator (smoking vaccine) – smoking withdrawal
Professors Mathematics or science: Arago, Berzelius, Biot, Curie, Frankenheim, Lehmann, Liebig, Mitscherlich, Ostwald, Pasteur, Reinitzer, Wöhler Mineralogy: Delafosse, Groth, Haüy, Neumann, Other employment: Brewster (editor), Romé de l'Isle (cataloguer), Sohncke (meteorological service), Wollaston (physician) Independently wealthy: Barlow, Herschel, Huygens In the nineteenth century there were informal schools of crystallography researchers in France (Arago, Biot, Curie, Delafosse, Haüy, Pasteur), Germany (Frankenheim, Groth, Lehmann, Liebig, Mitscherlich, Neumann, Reinitzer, Sohncke, Wöhler) and England (Barlow, Brewster, Herschel, Wollaston). Until the founding of Zeitschrift für Krystallographie und Mineralogie by Paul Groth in 1877 there was no lead journal for the publication of crystallographic papers. The majority of crystallographic research was published in the journals of national scientific societies, or in mineralogical journals. The inauguration of Groth's journal marked the emergence of crystallography as a mature science independent of geology.
DNA nanotechnology uses the unique molecular recognition properties of DNA and other nucleic acids to create self-assembling branched DNA complexes with useful properties. DNA is thus used as a structural material rather than as a carrier of biological information. This has led to the creation of two-dimensional periodic lattices (both tile-based and using the DNA origami method) and three-dimensional structures in the shapes of polyhedra. Nanomechanical devices and algorithmic self-assembly have also been demonstrated, and these DNA structures have been used to template the arrangement of other molecules such as gold nanoparticles and streptavidin proteins. DNA and other nucleic acids are the basis of aptamers, synthetic oligonucleotide ligands for specific target molecules used in a range of biotechnology and biomedical applications.
Taxodioxylon gysaceum is an extinct species of conifer presently found as fossil wood. Samples of the same wood in various stages of degradation were collected from a forest in Italy, originally existing during the Pliocene period. These samples were milled and filtered into different fractions by coarseness before steam distillation was utilized to extract terpenes. The extraction was then analyzed through GC/MS. The comparative degree of degradation was determined by analysis of holocellulose contents in each sample. Holocellulose refers to the fraction of plant biomass that includes cellulose and hemicellulose but excludes lignin. These carbohydrates are broken down during decomposition, and so their concentrations can be used as a measure of the degree of degradation. A variety of terpenes were detected in the degraded lignite samples, including more than 10% ferruginol, between 5 and 10% podocarpodiol, and less than 5% of sugiol. These compounds were hypothesized to have become more prevalent in the degraded sample due to preferential decomposition of other compounds. The presence of these terpenes in this sample suggest that the organism belongs to the Cupressaceae, Podocarpaceae, or Taxodiaceae families. Given the specific combination of terpenes present, the sample was identified as Taxodioxylon gypsaceum. This combination of terpenes has also been detected in other samples known to be Taxodioxylon gypsaceum, further supporting this identification.
Antigen-naive T cells expand and differentiate into memory and effector T cells after they encounter their cognate antigen within the context of an MHC molecule on the surface of a professional antigen presenting cell (e.g. a dendritic cell). Appropriate co-stimulation must be present at the time of antigen encounter for this process to occur. Historically, memory T cells were thought to belong to either the effector or central memory subtypes, each with their own distinguishing set of cell surface markers (see below). Subsequently, numerous new populations of memory T cells were discovered including tissue-resident memory T (Trm) cells, stem memory TSCM cells, and virtual memory T cells. The single unifying theme for all memory T cell subtypes is that they are long-lived and can quickly expand to large numbers of effector T cells upon re-exposure to their cognate antigen. By this mechanism they provide the immune system with "memory" against previously encountered pathogens. Memory T cells may be either CD4+ or CD8+ and usually express CD45RO. Memory T cell subtypes:
Sources: en.wikipedia.org
Allow the sealed vial to reach room temperature before opening to reduce condensation. Use a suitable solvent and gentle mixing rather than vigorous agitation. Follow the supplier's solubility information when available.
Aliquots limit repeated thawing and refreezing and repeated vial opening, both of which can promote degradation. They also reduce the chance of contaminating an entire batch. Single-use portions should be labeled with identity, concentration, solvent, and date.
Inspect the package for damage and confirm that temperature indicators or data loggers stayed within the specified range. Check the vial condition and labeling before placing it into storage. Record any excursion or discrepancy for the supplier or quality system.
Common solvents include sterile water, phosphate-buffered saline, and water-acetonitrile mixtures. The choice depends on the peptide's solubility profile and the buffer compatibility for the intended application. Manufacturers often provide a recommended solvent on the product information sheet.